# US 2002/0082214 A1 · Alpha 1-antitrypsin preparation as well as a method for producing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0082214 A1
- Document ID: US20020082214A1
- Status: Published application
- Kind: A1
- Application number: 09/963,341
- Filed: 2001-09-24
- Published: 2002-06-27
- Earliest claimed: 1997-06-10
- Assignees: Baxter Aktiengesellschaft
- Inventors: Erwin Mattes; H. Peter Matthiessen
- Web page: https://patentgrep.com/patent/US20020082214A1

## CPC

- C07K 14/8125: {Alpha-1-antitrypsin}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A native, chromatographically purified α1-AT preparation having a purity of at least 0.7 PU/mg protein and a relative plasma α1-AT activity of at least 120% is disclosed. The ratio of active to inactive α1-AT is higher than in plasma. Furthermore, a method of producing this preparation is disclosed, as well as the use of a carrier material, e.g. an inorganic carrier material such as hydroxylapatite for separating active α1-AT from inactive α1-AT.

## Claims

### Claim 1

A native chromatographically purified α1-AT preparation, characterized in that it contains at least the isomer having a pI value of between 4.3 and 4.4, has a purity of at least 0.7 PU/mg protein and a relative plasma-α1-AT activity of at least 120% and that its portion of inactive α1-AT is less than 10%.

### Claim 2 (depends on 1)

A preparation according to claim 1, characterized in that it is present as a pharmaceutical preparation.

### Claim 3 (depends on 1, 2)

A preparation according to claim 1 or 2, characterized in that it is purified from a plasma pool.

### Claim 4 (depends on 1, 2, 3)

A preparation according to any one of claims 1 to 3, characterized in that it has a purity of more than 0.9 PU/mg, preferably more than 1.0 PU/mg, in particular more than 1.1 PU/mg.

### Claim 5 (depends on 4)

A preparation according to claim 4, characterized in that it has a purity of more than 1.2 PU/mg.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A preparation according to any one of claims 1 to 5, characterized in that its portion of inactive α1-AT is less than 5%, in particular less than 2%.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A preparation according to any one of claims 1 to 6, characterized in that it is free from inactive α1-AT.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A preparation according to any one of claims 1 to 7, characterized in that the α1-AT is a preservative one.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A preparation according to any one of claims 1 to 8, characterized in that the isomer distribution of the α1-AT corresponds to that of native protein, in particular to a quadruplet band pattern visible at isoelectric focussing.
